Nativis Announces Name Change To EMulate Therapeutics, Inc.

CRO Selected to Conduct Pivotal Clinical Studies for Newly Diagnosed GBM


Nativis, Inc., today announced the Company has changed its name to EMulate Therapeutics, Inc.The name change is effective immediately for the clinical stage, therapeutic device company, which is developing non-invasive treatments for cancers and other serious diseases.

In making the announcement, Chris Rivera, Chief Executive Officer, said, “the renaming of the company to EMulate Therapeutics, Inc. more clearly represents and describes the technology being used to treat cancers and other serious diseases by using the recorded magnetic signature of a chemical, biochemical or biological agent to “emulate” the effects of that agent using the company’s ultra-low radio frequency energy (ulRFE®) system.” The ulRFE signal is created by measuring and recording the oscillating magnetic field produced by drugs or other molecules in solution. The signal is then used to reproduce the recorded magnetic field using an electromagnetic coil worn by the patient externally.

EMulate Therapeutics’ ulRFE system is currently in clinical trials in patients diagnosed with glioblastoma (GBM). The company is also preparing a Humanitarian Device Exception (HDE) application for the treatment of pediatric patients diagnosed with diffuse midline glioma (including diffuse intrinsic pontine glioma) and an application to secure regulatory approval for treatment of GBM in the European Union and other markets.

In further news, EMulate Therapeutics announced the selection of a clinical research organization (CRO) to conduct pivotal clinical studies for the Voyager system for the treatment of GBM. In making this announcement, Rivera revealed that CurAccel, LLC of Newtown, PA, has been selected to conduct a large, global pivotal study in patients with newly diagnosed GBM.

“We are excited to have an agile and entrepreneurial CRO partnering with EMulate Therapeutics on this critically important pivotal study,” stated Rivera. “The data in previously conducted feasibility studies show the EMulate Therapeutics Voyager device is safe for the treatment of GBM, with encouraging clinical response. We are now moving on to the all-important pivotal clinical studies as a precursor to a marketing authorization application to FDA for treatment of adults with GBM.

“CurAccel is grateful for this opportunity to play a part in the success of EMulate Therapeutics’ clinical development to deliver novel treatment to benefit GBM patients and their families,” commented Roberta Sapone, CurAccel’s Director of Business Development. “We look forward to propelling this partnership to support the goal of EMulate Therapeutics to bring this innovative treatment to market.”

The new EMulate Therapeutics web site can be viewed at

About EMulate Therapeutics 
Founded in 2002 and headquartered in Seattle, WA, EMulate Therapeutics is a clinical-stage therapeutic device company. EMulate Therapeutics has invented and patented a groundbreaking technology that utilizes precisely targeted, ultra-low radio frequency energy (ulRFE) to specifically regulate metabolic pathways on the molecular and genetic levels – without chemicals, radiation or drugs – delivered via simple-to-use non-invasive devices called EMulate Therapeutics Voyager system. The company’s goal is to transform disease treatment on a global scale with ulRFE that can potentially be applied to a wide range of medical conditions, as well as to veterinary medicine and non-medical applications. EMulate Therapeutics’ initial focus is on the treatment of patients with brain cancer, who are not well served by conventional standard of care therapies, which often results in poor outcomes and devastating side effects. Additional pre-clinical work is focused on exploring new applications in other oncology settings and pain management. The EMulate Therapeutics Voyager system is an investigational medical device, limited by United States law to investigational use only.

About CurAccel 
CurAccel is a full-service global contract research organization (CRO) of outsourced early and late phase services for drug and device development that caters to small and mid-sized pharmaceutical, biotechnology, and medical device industries. CurAccel’s vision, “to become the industry leader in driving the science to standard of care,” truly exemplifies the focus and reason for our partnership with our clients.

Media Contact: 
Dennis Kroft

Back to News